news
HHS and VA Back Mark Cuban to Develop Ibogaine for PTSD
The U.S. Department of Health and Human Services announced a partnership with Mark Cuban's pharmaceutical company to manufacture ibogaine for veterans with PTSD. The initiative includes a $20 million commitment to fund a real-world evidence clinical network tracking outcomes. It marks the first direct federal effort to study and produce an African root alkaloid long categorized as Schedule I.
The U.S. Department of Health and Human Services announced a partnership with Mark Cuban's pharmaceutical company to manufacture ibogaine for veterans with PTSD. The initiative includes a $20 million commitment to fund a real-world evidence clinical network tracking outcomes. It marks the first direct federal effort to study and produce an African root alkaloid long categorized as Schedule I.
The architecture take
I used to think federal backing for ibogaine was a decade away. The compound triggers a grueling 36-hour hallucinogenic ordeal, but it does something conventional SSRIs can't: it resets kappa-opioid and dopamine signalling while driving brain-derived neurotrophic factor, clearing out frozen survival patterns in a blown-out nervous system. I've tracked veterans who slipped down to clinics in Mexico because nothing in American hospitals touched their hypervigilance. Now HHS is committing $20 million to follow real-world treatment data instead of criminalising it. The medical hurdle was never whether it worked; it was cardiac safety. Ibogaine lengthens the QT interval, so you need continuous cardiac monitoring while the mind rewires. Bringing Mark Cuban into the manufacturing conversation tells me Washington wants low-cost supply ready the minute clinical protocols settle. I was wrong about timing. Watch state veteran groups push for compassionate-use treatment suites before the year ends.